Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Impact of New U.S. Medicare Pricing Policies on Global Pharmaceutical Markets

2d ago September 14, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

A new study indicates that the U.S. Medicare's 'Most-Favored-Nation' pricing policy could lead pharmaceutical companies to increase prices or delay product launches. This policy affects how medicines are priced based on other high-income countries, which could have global repercussions. For Iran, this may impact access to affordable medications as pricing strategies shift.

🔍 Quick Context Guide
💡 Bottom Line: U.S. Medicare's new pricing policy could disrupt global pharmaceutical markets, affecting drug affordability in countries like Iran.

👥 Key Players

U.S. Medicare MENTIONED
Government health insurance program
"Sets pricing policies that can influence global pharmaceutical pricing strategies."
Pharmaceutical Manufacturers MENTIONED
Companies producing medications
"Their pricing decisions directly affect drug availability and affordability in markets like Iran."
The Lancet MENTIONED
Medical journal publishing research
"Provides credible research that shapes public and policy discussions on health economics."

📰 What Happened

A study indicates that the U.S. Medicare's new pricing policy could lead pharmaceutical companies to increase drug prices or delay launches. This change could have significant implications for global drug pricing strategies.

  • The Most-Favored-Nation pricing policy ties Medicare drug prices to those in other high-income countries.
  • The study suggests that this could result in Medicare savings that exceed the annual sales of the medicines used for pricing comparisons.

💡 Why It Matters

🇮🇷 For Iran: Iran may face increased costs and reduced access to medications as global pricing strategies shift in response to U.S. policies.
🌍 Regional: Other countries in the region may also experience similar pressures on drug pricing and availability.
🌐 International: This policy could lead to increased tensions between pharmaceutical companies and governments over drug pricing and access.

📚 Background

The Most-Favored-Nation pricing policy aims to lower drug costs for U.S. consumers by aligning prices with those in other wealthy nations, but it may have unintended consequences globally.

Global pharmaceutical pricing Healthcare policy reforms
📡 Source: NEUTRAL
📊 Confidence: 70%
The Lancet is a reputable medical journal known for peer-reviewed research, making it a reliable source for health-related studies.

A new modeling study published in The Lancet suggests that U.S. Medicare's new "Most-Favored-Nation" pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push pharmaceutical manufacturers to raise prices or delay launches. For about three in four medicines studied, the resulting Medicare savings would be worth almost four times that medicine's entire annual sales in the country used to set its price, potentially giving manufacturers a strong incentive to change how they price and launch products outside the U.S.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →